Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis |
| Type de publication | Journal Article |
| Year of Publication | 2022 |
| Auteurs | Fischer K, Lellouche N, Damy T, Martins R, Clementy N, Bisson A, Lesaffre F, Espinosa M, Garcia R, Degand B, Serzian G, Jourda F, Huttin O, Guichard J-B, Devilliers H, Eicher J-C, Laurent G, Guenancia C |
| Journal | ESC HEART FAILURE |
| Volume | 9 |
| Pagination | 740-750 |
| Date Published | FEB |
| Type of Article | Article |
| ISSN | 2055-5822 |
| Mots-clés | Cardiac amyloidosis, Cardiac resynchronization therapy, heart failure, Implantable cardioverter defibrillator, pacemaker |
| Résumé | {Aims: Cardiac resynchronization therapy (CRT) is highly effective in dilated cardiomyopathy (DCM) patients with impaired left ventricular ejection fraction (LVEF) and left bundle block branch. In cardiac amyloidosis (CA) patients, left ventricular dysfunction and conduction defects are common, but the potential of CRT to improve cardiac remodelling and survival in this particular setting remains undefined. We investigated cardiovascular outcomes in CA patients after CRT implantation in terms of CRT echocardiographic response and major cardiovascular events (MACEs). Methods and results: Our retrospective study included 47 CA patients implanted with CRT devices from January 2012 to February 2020, in nine French university hospitals (77 +/- 6 years old, baseline LVEF 30 +/- 8%) compared with propensity-matched (1:1 for age, LVEF at implantation, and CRT indication) DCM patients with a CRT device. CA patients had lower rates of CRT response (absolute delta LVEF >= 10%) compared with DCM patients (36% vs. 70% |
| DOI | 10.1002/ehf2.13663 |